Treatment & Procedure
Cancer blood test (multi-cancer early detection)
Biohacking
A multi-cancer early detection test uses a single blood draw to look for signals of many cancer types at once, including those for which there is otherwise no screening. The first randomized trial on it is now available. It shows a test that rarely raises a false alarm, and it missed its primary goal.
In short
NHS-Galleri enrolled 142,250 people aged 50 to 77 in England, with up to three annual blood draws. Twelve prespecified cancer types were counted, which together account for two thirds of annual cancer deaths. The test rarely raises a false alarm, specificity was 99.5 to 99.6 percent, and it correctly predicted the organ of origin in more than nine out of ten cases. The primary goal, fewer cancers at stage III or IV, was missed: incidence rate ratio 1.03 (95% CI 0.92–1.14; p = 0.63). The test finds about three in ten cancers, so an unremarkable result is not an all-clear.
What the test is and how it works
A multi-cancer early detection test analyzes a blood sample for signals that point to a cancer. If it is positive, it also predicts which organ the signal most likely comes from. In NHS-Galleri, people with a positive result were referred specifically for workup into the appropriate diagnostic pathways of the British National Health Service.
The idea: a single blood draw covers many cancer types, including those for which there is no established screening. If cancer is found earlier as a result, fewer people should be diagnosed only at the advanced stage III or IV. NHS-Galleri measured exactly this decline in late diagnoses as its primary endpoint.
What is well supported
Test performance under real-world conditions is well supported. Over three annual rounds, the result was positive in 0.8 to 1.0 percent of those tested. Specificity was 99.5 to 99.6 percent, so false alarms are rare relative to everyone tested. When a cancer was actually present, the prediction of the organ of origin was correct in 91 to 94 percent of cases. In total, the test found 937 cancers.
It is also established that such a test can be evaluated properly: NHS-Galleri is the first randomized trial ever of a multi-cancer early detection test. Blood was drawn in both groups but analyzed only in the test group; in the control group it was stored. Fewer than one percent of participants had study-related adverse events, none of them serious.
What the studies show
Sasieni 2026 — NHS-Galleri, main result
142,250 people aged 50 to 77, 71,122 in the test group and 71,128 in the control group, both also receiving usual screening. The primary endpoint was stage III or IV cancer among twelve prespecified cancer types, assessed after three screening rounds and at least twelve months of follow-up. The incidence rate ratio was 1.03 (95% CI 0.92–1.14; p = 0.63), no difference. For the most important secondary endpoint, stage IV cancer, it was 0.86 (95% CI 0.74–1.00). The trial was funded by the test manufacturer Grail.
Neal 2026 — NHS-Galleri, test performance
Prespecified, descriptive analysis of the test group over three rounds, without hypothesis testing. 722 of 70,325, 518 of 64,498 and 561 of 62,323 results were positive. Of these, cancer was confirmed in 58.0, 50.4 and 45.8 percent. Sensitivity for all cancer types was 26.7 to 37.2 percent per round, and for the twelve prespecified cancer types 47.6 to 63.4 percent. Specificity was 99.5 to 99.6 percent, and accuracy for the organ of origin 91.1 to 93.6 percent.
Where the data stop
The primary endpoint was missed. Anyone reading that the test reduces late diagnoses is reading a secondary finding: for stage IV alone the ratio was 0.86, but the confidence interval extends to 1.00. That is a signal, not proof. Whether the test prevents cancer deaths is not yet answered by the trial; the authors consider further follow-up necessary.
The test finds about three in ten cancers, and for the twelve prespecified types about half to just under two thirds. An unremarkable result is therefore not an all-clear. And even though false alarms are rare relative to everyone tested: among the positive results, no cancer was confirmed in 42 to 54 percent, depending on the round. For these people, a workup follows that finds nothing. In addition, both the main trial and the test performance analysis were funded by the manufacturer.
Status, approval and legal
NHS-Galleri tested the Galleri test from the manufacturer Grail as an addition to usual screening, not as a replacement. Based on these data, it is not a substitute for established early detection. Anyone who skips colonoscopy, mammography or skin checks because of an unremarkable result has made things worse, not better.
Safety
The blood draw itself is unproblematic: in NHS-Galleri, fewer than one percent of participants had study-related adverse events, none of them serious. The real risks lie in the information. A positive result leads to further diagnostic testing, which found no cancer in 42 to 54 percent of those who tested positive. A negative result can create a false sense of security, even though the test does not detect most cancers. The axis rates the state of the data, not the danger.
BK-Score Well studied – effect not confirmed
| Human evidence | 8 | |
|---|---|---|
| Mechanism | 6 | |
| Safety data | 7 | |
| Hype gap | 7 | |
| Track record of use | 4 |
The evidence is high because this is the first randomized trial ever of a multi-cancer early detection test – and its primary endpoint was missed. NHS-Galleri enrolled 142,250 people aged 50 to 77, three blood draws over two years, twelve prespecified cancer types that together account for two thirds of annual cancer deaths. The incidence rate ratio for stage III or IV was 1.03 (95% CI 0.92–1.14; p = 0.63). The frequently cited reduction in late diagnoses comes from a secondary finding (stage IV: 0.86) whose confidence interval almost touches one. The hype gap is the highest item: what is being marketed is a test that finds about three in ten cancers – and whose unremarkable result is not an all-clear.
The score rates the state of knowledge, not the substance. “Safety data 9” means well studied – not harmless. “Track record of use 9” means used long and widely – that is not proof of efficacy.
Subjective assessment by Biohacking Kompakt based on published scoring rules – not a scientific rating and not a medical recommendation. Rules and all ratings (German)
Frequently asked questions about the cancer blood test (multi-cancer early detection)
What can a cancer blood test do?
With a single blood draw it looks for signals of many cancer types and, if the result is positive, predicts the likely organ of origin. In NHS-Galleri it found 27 to 37 percent of all cancers, depending on the round.
Does the test reduce the number of late cancer diagnoses?
Not in the main result. In NHS-Galleri the ratio for stage III or IV cancer was 1.03 (95% CI 0.92–1.14), so no difference from usual screening.
Why do people still say the test reduces late diagnoses?
That refers to a secondary endpoint: for stage IV alone the ratio was 0.86, but the confidence interval extends to 1.00. That is a signal, not proof.
Is an unremarkable result an all-clear?
No. The test finds about three in ten cancers. It does not replace colonoscopy, mammography or skin checks.
How often is a positive result a false alarm?
Rarely, relative to everyone tested: specificity was 99.5 to 99.6 percent. Relative to the positive results, however, no cancer was confirmed in 42 to 54 percent, depending on the round.
Related
- Same sectionWhole-body MRI (self-pay screening)
- Same sectionRed light / photobiomodulation (PBM)
- Same sectionChelation therapy
- Same sectionScreenings
- Same sectionLipoprotein(a)
- Same sectionHearing & dementia (hearing care)
Sources
Open in the database – with search, filters and comparison (German app)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-10-05.